- Home
- EPAM vs MRNA Comparison
EPAM vs MRNA Comparison
Compare EPAM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- MRNA
- Stock Information
- Founded
- EPAM 1993
- MRNA 2010
- Country
- EPAM United States
- MRNA United States
- Employees
- EPAM N/A
- MRNA N/A
- Industry
- EPAM EDP Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPAM Technology
- MRNA Health Care
- Exchange
- EPAM Nasdaq
- MRNA Nasdaq
- Market Cap
- EPAM 8.9B
- MRNA 9.2B
- IPO Year
- EPAM 2012
- MRNA 2018
- Fundamental
- Price
- EPAM $181.01
- MRNA $27.08
- Analyst Decision
- EPAM Buy
- MRNA Hold
- Analyst Count
- EPAM 14
- MRNA 15
- Target Price
- EPAM $217.50
- MRNA $36.69
- AVG Volume (30 Days)
- EPAM 914.8K
- MRNA 12.1M
- Earning Date
- EPAM 11-06-2025
- MRNA 11-06-2025
- Dividend Yield
- EPAM N/A
- MRNA N/A
- EPS Growth
- EPAM N/A
- MRNA N/A
- EPS
- EPAM 6.55
- MRNA N/A
- Revenue
- EPAM $5,297,859,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- EPAM $16.65
- MRNA N/A
- Revenue Next Year
- EPAM $7.20
- MRNA $10.38
- P/E Ratio
- EPAM $27.47
- MRNA N/A
- Revenue Growth
- EPAM 14.26
- MRNA N/A
- 52 Week Low
- EPAM $138.15
- MRNA $23.04
- 52 Week High
- EPAM $269.00
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- EPAM 70.66
- MRNA 55.06
- Support Level
- EPAM $155.00
- MRNA $23.04
- Resistance Level
- EPAM $183.83
- MRNA $25.56
- Average True Range (ATR)
- EPAM 5.99
- MRNA 1.58
- MACD
- EPAM 2.63
- MRNA 0.07
- Stochastic Oscillator
- EPAM 89.58
- MRNA 65.26
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.